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Abstract 
Dendritic cells (DCs) play a central role in the initiation and regulation of innate and adaptive 
immune responses and have increasingly been applied as vaccines for cancer patients. Ex vivo 
generation and antigen loading of monocyte-derived DCs allows a controlled maturation, with 
the aim of imprinting different DC functions that are essential for their subsequent induction 
of a T cell-mediated anti-tumor response. A better understanding of how DCs control T cell 
immunity is important for the design of novel DC-based cancer vaccines with improved 
clinical efficiency. The aim of this thesis was to evaluate how different maturation conditions 
used for generation of clinical grade DC-based cancer vaccines affect their capacity to assist 
type-1 polarized immune responses, important for elimination of cancer.  
Monocyte-derived DCs from healthy blood donors and chronic lymphocytic leukemia (CLL) 
patients were matured using two different types of cocktails; the “standard” maturation 
cocktail for human DC-based cancer vaccines consisting of TNF-α, IL-1β, IL-6 and PGE2 
(PGE2DCs) and the more recently established α-type 1-polarized DC cocktail consisting of 
TNF-α, IL-1β, IFN-γ, IFN-α, and p-I:C (αDC1s).  
Recent data from mouse models indicate that the ability of vaccine DCs to induce a desirable 
type 1-polarized immune response is strongly dependent on their ability to induce a CXCR3-
dependent recruitment of IFN-γ-producing natural killer (NK) cells into vaccine-draining 
lymph nodes.  We found that αDC1s from healthy blood donors secrete substantial amounts 
of the CXCR3 ligands (CXCL9/CXCL10/CXCL11). In contrast, no measurable production of 
these chemokines was found in PGE2DCs. Functional studies revealed that supernatants from 
mature αDC1s recruited NK cells and further, αDC1s induced IFN-γ production in autologous 
NK cells, but only if concurrent CD40 ligation was provided.  
Despite previous reports of dysfunctional DCs in CLL patients, we found that αDC1s 
generated from CLL patients also produced substantial amounts of CXCR3-ligands in a 
sustained fashion. Functional studies demonstrated that αDC1s from CLL patients were 
superior recruiters of NK cells and potential CD40 ligand-expressing NKT cells compared to 
PGE2DCs. Importantly, loading of αDC1s with necrotic CLL cells had no negative impact on 
chemokine production. It has most recently been shown that autologous DC vaccines 
indirectly prime naïve T cells in vivo by acting as immune adjuvant that transfer antigens to 
recruited endogenous DC-precursors. In our final study we investigated the ability of 
allogeneic (foreign) DCs to recruit and differentiate “bystander” monocytes into functional 
DC-like cells in vitro. We found that allogeneic DC1s efficiently recruited monocytes and 
Th1-associated lymphocytes from CLL patients. Finally, monocytes primed in such αDC1 but 
not PGE2DC-induced environment seem to undergo maturation toward Th1-deviating DCs. 
In conclusion, this thesis supports the therapeutic use of DC1-based vaccines in the 
traditional autologous setting and further indicates that allogeneic DC1s could be used as a 
source of adjuvant and a vehicle for tumor antigen delivery to evoke Th1-polarized immune 
responses against human cancers.  
Keywords: αDC1, PGE2DC, dendritic cells, natural killer cells, T cells, CLL, vaccines 
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POPULÄRVETENSKAPLIG SAMMANFATTNING 
Syftet med arbetet som ligger till grund för denna avhandling var att försöka 
utveckla en alternativ behandlingsmetod mot cancer där man använder sig av 
patientens eget immunförsvar. Metoden som här presenteras är baserad på ”aktiv 
immunterapi” där man via vaccination försöker få igång ett specifikt immunsvar 
mot den befintliga tumören. Vaccinet tillverkas genom att man ur ett blodprov 
renar fram en viss typ av immunförsvarets vita blodkroppar, så kallade 
dendritiska celler. Dessa celler odlas sedan i provrör tillsammans med olika 
inflammatoriska ämnen och ”laddas” med tumörämnen från önskad tumörtyp. I 
denna konstgjorda inflammatoriska miljö ”lär” man vaccincellen att den aktuella 
tumörtypen är farlig och bör elimineras. Tanken är sedan att cancerpatientens 
immunförsvar genom vaccineringen med dessa manipulerade budbärarceller ska 
omprogrammeras till att uppleva den egna tumören som något 
kroppsfrämmande som måste elimineras.  
I mitt avhandlingsarbete har jag använt vita blodkroppar från friska blodgivare 
och från patienter med kronisk lymfatisk leukemi (KLL) för att i provrör försöka 
simulera den immunologiska reaktion som kan tänkas ske i samband med en 
vaccination. KLL är en vanlig form av blodcancer. Hos ungefär en tredjedel av 
denna patientgrupp uppträder sjukdomen i en aggressiv form och trots 
konventionell behandling är prognosen för dessa patienter mycket dålig. 
Behovet av nya behandlingsmetoder är därför stort. Genom att i olika 
försöksmodeller odla vita blodkroppar från patientblodprov med potentiella 
vaccinkandidater har jag kunnat studera olika centrala skeden i den 
immunologiska kaskadreaktion som krävs för ett effektivt tumördödande 
immunsvar. Utifrån resultat från dessa försök har jag kommit fram till en 
mycket lovande vaccinkandidat som tycks besitta flera nyckelegenskaper som 
sannolikt behövs för att få igång ett effektivt immunsvar mot cancer.   
Framtidens behandling av idag obotliga cancerformer kommer troligen att kräva 
kombinationsbehandlingar. Tänkbart är att ge den typ av vaccinceller som jag 
studerat i kombination med redan etablerade terapier såsom strålning och 
cytostatika. Önskvärt är att ta fram skräddarsydda behandlingar för varje enskild 
patient som effektivt dödar tumörceller men lämnar friska celler opåverkade. 
Min förhoppning är att resultat som presenteras i denna avhandling kan vara ett 
bidrag till vår ökade förståelse för hur vi kan använda oss av vårt enormt 
komplexa immunförsvar i kampen mot cancer. 
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INTRODUCTION 
GENERAL BIOLOGY OF THE IMMUNE SYSTEM 
The immune system is an amazingly complex network of cells, tissues, and 
organs that work together to protect the body from harmful processes such as 
microbial infections, cancer and autoimmune disorders.  
This system can be divided into the innate immunity and the adaptive immunity. 
The innate or natural immunity is the first line of defense and a type of general 
protection, including physical barriers of the body (e.g. skin, mucosa), chemical 
barriers (e.g. secretions and enzymes), and other soluble factors (e.g. cytokines, 
chemokines and the complement system). It also includes innate leukocytes such 
as natural killer (NK) cells, mast cells, and phagocytic cells (e.g. monocytes, 
dendritic cells (DCs), macrophages and neutrophils (Parkin 2001).  
Among the phagocytes, DCs have powerful key functions in the immune 
system. They capture antigens in peripheral tissues and migrate to secondary 
lymphoid organs. There, they may provide cells of the adaptive, also called 
specific, immunity such as T and B lymphocytes with pathogen-related 
information from the affected tissue and thereby activate suitable antigen-
specific immune responses (Steinman 1991; Banchereau 1998).  
In contrast to the fast and unspecific innate immunity, the adaptive immune 
response has specificity for distinct molecules and provides the immune system 
with the ability to recognize and remember specific pathogens. The memory 
function of adaptive immunity enables more vigorous responses to repeated 
exposures to the same microbe. DCs not only provide an important link between 
the innate and adaptive immunity, they also have a key role in the polarization 
of adaptive immune responses and in that way contribute to the selection of the 
most efficient effector mechanisms against a particular pathogen (Abbas 2010). 
This thesis is focused on DCs and how they may induce desirable polarized 
immune responses of importance for fighting tumor cells. However, endogenous 
DCs in cancer patients are often defective due to tumor-induced 
immunosuppression, resulting in impaired development of anti-cancer immunity 
(Yang 2004; Pinzon-Charry 2005). To overcome this obstacle to an effective 
cancer treatment, immunotherapeutic strategies have been purposed, whereby 
DCs are loaded with tumor antigens and activated ex vivo in a non-suppressive 
environment. The main focus of this thesis is to in vitro evaluate how different 
maturation conditions used for generation of clinical grade DC-based cancer 
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vaccines affect their capacity to assist type-1 polarized immune responses, 
critical for elimination of cancer. 
Dendritic cells 
DCs are highly specialized antigen-presenting cells (APCs) which in contrast to 
other APCs, such as macrophages and B cells, are able to activate naïve T cells. 
Therefore DCs have a unique ability to initiate and regulate immune responses 
against foreign antigens. Most likely, DCs also play a key role in T cell 
tolerance to self antigens, thereby avoiding the induction of autoimmune 
reactions (Steinman 1991; Banchereau 1998; Steinman 2003). There is 
accumulating evidence for the existence of different subsets of DCs that are 
responsible for this broad range of responses.  
Origin and types of dendritic cells 
Various types of DCs with differences in phenotype, function and tissue 
distribution indicate the coexistence of heterogeneous DC populations (Hart 
1997; Ueno 2007). Despite extensive research on DC development, the origin of 
DCs is still a controversial issue. Briefly, according to current opinion, DCs are 
generated from either lymphoid or myeloid precursors of hematopoetic origin, 
and intermediate precursors of these lineages home to different sites of potential 
antigen entry where they differentiate into DCs.  
A subset of circulating DC-precursor cells that express the integrin CD11c
 
and 
receptor for the cytokine and growth factor granulocyte-macrophage colony-
stimulating factor (GM-CSF) may differentiate into conventional myeloid DCs 
under the influence of GM-CSF and IL-4. Myeloid DCs are thought to be 
closely related to monocytes, macrophages and granulocytes.  
In contrast, CD11c
- 
DC precursors express low levels of the GM-CSF receptor 
but high amounts of the IL-3 receptor, mature in response to IL-3 and CD40 
ligation, and differentiate into non-conventional plasmacytoid DCs (Grouard 
1997; Rissoan 1999). Plasmacytoid DCs were first reported as a cell type 
resembling plasma cells (Lennert 1958) and seem to have a tight developmental 
link to lymphocytes (Facchetti 1988; Galy 1995; Facchetti 2003). There is also 
an alternative hypothesis proposing the existence of a common DC precursor in 
blood that can give rise to all subsets of DCs (del Hoyo 2002). 
The possibility that blood monocytes traffic into tissues and differentiate into 
DCs upon certain stimuli has become more and more accepted. Local 
mechanisms that mediate differentiation of such monocyte-derived DCs 
(MoDCs) are not fully elucidated. However, the process of transendothelial 
migration itself has in vitro been shown to result in differentiation of monocytes 
into DCs (Randolph 1998). Local production of the DC-differentiating factor 
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GM-CSF by endothelial cells (Kaushansky 1989) and/or by co-recruited natural 
killer (NK) and natural killer T (NKT) cells (Hegde 2007; Zhang 2007) are 
another potential mechanism by which recruited monocytes are induced to 
differentiate into DCs.  
According to several recent studies, MoDCs are a true component of the DC 
network in vivo but they only appear “on demand” at sites of inflammation 
(Trapani 2002; Tacke 2006). Data from Leon et al (Leon 2007) reveal an 
important role for this inflammatory MoDC type in mediating an effective 
immune response at a time when other DC subsets may not be capable of coping 
with the infection. They observed a massive influx of monocytes at the site of 
infection and in the draining lymph node after inoculation of the parasite L. 
major. These monocytes turned into MoDCs in both locations and evidence was 
presented suggesting that MoDCs from the infected site had migrated to the 
lymph node. It was convincingly shown that the MoDC subset was the only DC 
population that presented L. major antigens and were able to provide antigen-
specific T cells with the desirable type 1-polarizing signals required to generate 
a protective response against L. major infection.  
DC maturation and antigen presentation 
As immature cells, the heterogeneous subsets of DCs work as immunological 
sensors and screen the peripheral tissues for damaged cells and pathogens. 
“Danger signals” are then mediated by pathogen recognition receptors (PRRs), 
such as Toll-like receptors (TLRs) and C-type lectins that recognize various 
conserved microbial molecules called pathogen associated molecular patterns 
(PAMPs) (Pulendran 2004; Akira 2006). Immature DCs are efficient at 
capturing antigen. When antigen ingestion and processing take place in the 
presence of pro-inflammatory cytokines such as IL-1β, tumor necrosis factor 
(TNF)-α, and pathogen-associated danger signals, phenotypic and functional 
changes are induced. During this process of maturation, DCs up-regulate co-
stimulatory molecules such as CD40, CD80 and CD86 on their surface and 
produce large amounts of immunostimulatory cytokines and chemokines 
(Sallusto 1999; Langenkamp 2000).  
 
Chemokines are small chemotactic cytokines that guide the migration of 
immune cells within the body. Each DC population shows a unique spectrum of 
chemokine responsiveness that change during their development from peripheral 
immature antigen-capturing DCs to mature migrating DCs able to prime naive T 
cells. In general, immature DCs migrate in response to chemokines such as MCP 
chemokines (via CCR2), MIP-1α/β and RANTES (via CCR1, CCR3 and/or 
CCR5), that are inducible with inflammatory stimuli (Caux 2000). Upon 
maturation, DCs lose their responsiveness to these inflammatory chemokines 
and up-regulate the lymph node homing receptor CCR7 whereupon they acquire 
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responsiveness to lymphoid chemokines such as CCL19 and CCL21 (Steinman 
1991; Banchereau 1998; Sallusto 1998; Kellermann 1999). The maturing DCs 
therefore leave the affected tissues and migrate to T cell rich areas of draining 
lymphoid organs where, transformed into mature DC, they may present 
pathogen-derived peptides to antigen-specific naïve T cells and direct their 
differentiation into  effector or memory cells.  
 
During this maturation program DCs also up-regulate the expression of major 
histocompatibility complex (MHC) molecules. These are key molecules in the 
DC-mediated induction of adaptive immune responses and are furthermore of 
central importance for the whole immune system as they provide an ability to 
distinguish between "self" and "non-self". Every cell in our body displays the 
same set of unique “self” MHC molecules. Foreign molecules and cells that do 
not display the same MHC are treated as non-self and therefore attacked. In 
contrast to MHC Class I molecules, which are expressed on the surface of all 
nucleated cells, MHC Class II are mainly expressed on antigen-presenting cells 
such as DCs, macrophages, B cells and monocytes.  
T cells express antigen-specific T cell receptors (TCRs) which recognize a 
specific antigen that is presented as a processed peptide bound to self MHC 
molecules. TCRs of CD4
+
 T cells recognize processed peptides that are derived 
from internalized extracellular proteins and bound to MHC class II whereas 
TCRs of CD8
+
 T cells specifically recognize peptides, bound to MHC class I, 
which binds peptides derived from intracellular proteins. These proteins can be 
either self-antigens or antigens from intracellular pathogens (Abbas 2010). 
 
 
Figure 1. Dendritic cell maturation 
 
Furthermore, pathways of antigenic MHC class I cross-presentation in DCs have 
been suggested. Phagocytosed antigens that are normally processed and 
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presented by the phagosome-associated MHC class II pathway may escape to 
the cytosol and become processed by proteasomes and imported to the MHC 
class I antigen loading pathway (Albert 1998; Larsson 2001). This enables CD8
+
 
T cells to also recognize exogenous peptides expressed on MHC class I 
molecules.  
DC induced T cell activation and polarization: signal 1, 2, and 3 
After maturation DCs lose the antigen-sampling function and migrate to T cell 
areas of draining lymph nodes where they provide antigen-specific naïve CD4
+ 
T 
helper (Th) cells and CD8
+ 
T cells with pathogen-related information from the 
affected tissues. The capacity of DCs to induce immune responses is dependent 
on their effectiveness at delivering information about the identity and structure 
of the invading pathogen. This information is provided by the antigen specific 
“signal l” (Banchereau 1998; Reis e Sousa 2001), which is delivered when 
antigenic peptide-MHC complexes expressed on DCs are recognized by antigen-
specific TCRs on T cells.  
DCs may also provide T cells with information about the immunogenic potential 
of the invader. This type of information is transferred by ligation of co-
stimulatory molecules and referred to as “signal 2” (Cella 1997; Salomon 1998). 
The expression of co-stimulatory molecules on the surface of DCs mirrors the 
capacity of a certain pathogen to activate DCs. Pathogen-related activation of 
DCs may be generated by direct recognition of PAMPs (Pulendran 2004; Akira 
2006) through pathogen recognition receptors or indirectly by non-specific 
inflammatory responses induced by the invader. The combination of signal 1 
and 2 induces activation and proliferation of naïve T cells.  
This tightly regulated activation process is bi-directional whereby recently 
activated CD4
+ 
T helper (Th) cells rapidly up-regulate CD40 ligand (CD40L) 
which, via CD40 ligation, protects DCs from apoptosis and stimulates further 
up-regulation of MHC, co-stimulatory molecules, and increased cytokine 
production (Cella 1996; Bennett 1998; Ridge 1998; Schoenberger 1998). The 
expression and secretion of specific co-stimulatory molecules and cytokines 
represent a DC-delivered third signal, described as a polarizing “signal 3”, that 
drives the development of recently activated, naïve T helper cells towards either 
a Th1 or a Th2 polarized immune response and thereby regulates the character 
of the adaptive immune response (Gately 1998; Ohshima 1998; Kalinski 1999; 
Vieira 2000; Mailliard 2004). 
There are an increasing number of reports indicating that the capacity of DCs to 
polarize T helper cells is imprinted already in the periphery and depends on 
micro-environmental signals present during DC activation. For example, the 
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presence of IFN- during initial DC maturation is central for their capacity to 
produce the Th1-polarizing cytokine IL-12p70 upon CD40 ligation (Vieira 
2000; Xu 2003; Mailliard 2004; Ten Brinke 2007). The Th1-deviated cellular 
immunity is the most effective type of response against intracellular pathogens 
and cancer while Th2-polarized humoral immunity, mediated by antibody 
producing B lymphocytes, is effective at eliminating pathogens localized outside 
cells.  
 
Figure 2. Dendritic cell induced Th1-polarization, signal 1, 2, 3 
In addition to their capacity to induce adaptive cellular and humoral effector 
responses, DCs may also be involved in the induction of peripheral tolerance. 
During the steady state, in the absence of inflammation or infection, immature 
DCs migrate from peripheral tissues to lymphoid organs and present antigens to 
T cells in a tolerogenic way that induces antigen-specific T cell development 
into regulatory T cells, or alternatively induce T cell anergy or deletion 
(Steinman 2003). The well-established model for induction of peripheral T cell 
tolerance is described as an interaction between a naïve CD4
+ 
T cell and 
immature DC able to deliver signal 1 but not a costimulatory signal 2. However 
it has been suggested that this type of tolerance induction instead requires DCs 
providing signal 2 and is further dependent on a third tolerogenic signal (Albert 
2001). 
It is therefore worth noting that signals which generate phenotypically mature 
DCs, able to deliver signal 1 and 2, do not always seem to correlate with 
efficient T cell stimulatory capacity. This issue will be further discussed in later 
sections of this thesis.   
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Effector phase of the adaptive immunity 
Th1-polarized immunity  
The balanced cytokine production of different lymphocyte subsets plays an 
important role in the regulation of the human immune system. Following the 
antigen-specific signal 1 and co-stimulatory signal 2 (Schuler 1997; Banchereau 
1998; Schuler 2003), naïve CD4
+
 T cells start to produce the T cell-proliferative 
cytokine IL-2 acting both in an endocrine and paracrine manner. Depending on 
DC-mediated instructions, naïve CD4
+
 T cells develop into various subsets that 
provide different “helper” functions for other leukocytes of the immune system. 
This help is provided by cell interactions and/or by cytokine production. Th1 
cells produce IL-2 and IFN-γ, and together with IL-12 produced by certain DCs 
after CD40 ligation (Cella 1996; Bennett 1998; Ridge 1998; Schoenberger 
1998), they support the proliferation and differentiation of naïve CD8
+
 T cells 
into cytotoxic T lymphocytes (CTL) (Bennett 1998; Ridge 1998; Schoenberger 
1998). CTLs home to target cells in peripheral tissue where they induce 
apoptosis in malignant and virus-infected cells through the release of cytotoxic 
enzymes, such as granzyme and perforine or by Fas-ligand mediated pathways 
(Trapani 2002; Voskoboinik 2006). Th1 cells and CTLs thereby play a critical 
role in cellular immunity.  
Th2-polarized immunity 
Th2 cells are predominantly involved in humoral immunity against extracellular 
pathogens but also in the pathogenesis of allergy. They produce the B cell-
stimulatory cytokines IL-4 and IL-5, promote B cell proliferation, cytokine 
production and immunoglobulin (Ig) class switch and stimulate their 
transformation into antibody-producing plasma cells. Th2 cells also recruit and 
activate eosinophils and mast cells (Romagnani 1991; Mosmann 1996).  
Regulatory T cells and immune suppression 
Even though lymphocytes play a central role in inflammatory adaptive 
immunity, it is clear that they are also important for immune suppression and the 
maintenance of immune balance and tolerance to self-antigens. Different CD4
+
 
T cell subsets with regulatory functions have been described. The thymus-
derived naturally occurring FOXP3
+
CD4
+
CD25
high 
Tregs have been shown to 
suppress the activation, proliferation and effector function of both innate and 
adaptive lymphocytes as well as APCs. As dysfunction in FOXP3
+
 Tregs causes 
fatal autoimmune disease, allergy and immunopathology it has been concluded 
that this cell subset is central in the prevention of such conditions (Bennett 2001; 
Gambineri 2003; Hori 2003; Wohlfert 2008; Sakaguchi 2010).  
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Additional subsets of suppressive T cells have also been described. Periphery-
induced T regulatory type 1 (Tr1) cells may develop upon antigen stimulation 
via IL-10-dependent mechanisms. Tr1 mainly produce IL-10 and may thereby 
suppress antigen-specific effector T-cell responses. These regulatory cells are 
thought to regulate adaptive immune responses and have been suggested to be 
involved in the protection against autoimmunity (Groux 1997; O'Garra 2004; 
Roncarolo 2006)  
There is also a population of suppressive Th3 cells that like Tr1 cells, exert their 
regulatory function by cytokine production. Th3 cells are thought to be involved 
in the regulation of mucosal immunity and protect the gut mucosa to non-self 
antigens of non-pathogenic nature. Th3 cells mainly produce transforming 
growth factor-β (TGF-β) (Fukaura 1996), and may suppress the action of both 
Th1 and Th2 cells. (O'Garra 2004).  
 
 
Figure 3. Dendritic cells bridging innate and adaptive immunity  
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Innate lymphocytes 
Two important lymphocyte populations that work in close relation to DCs and T 
cells are the natural killer (NK) and NKT cells. These cells have been shown to 
express chemokine receptors such as CCR5 and CXCR3 similar to subsets of 
effector and memory lymphocytes of adaptive cellular immunity that home to 
peripheral sites of inflammation (Qin 1998; Sallusto 1998; Tensen 1999; 
Thomas 2003). Both NK and NKT cells express the NK cell markers CD56 and 
CD16. NKT cells also express the T cell marker CD3 and an invariant TCR 
(Lantz 1994) that recognize foreign and self-glycolipids presented by the non-
classical MHC class I molecule CD1d (Kawano 1997; Mattner 2005). 
NK cells are classically described as natural killers belonging to the innate 
immune system, due to their ability to kill tumor and virus infected cells without 
prior sensitization (Herberman 1979). Their activation is regulated by the 
balance between inhibitory and activating receptors (Bryceson 2006). Similar to 
CTLs, NK cells screen cells for presence of MHC class I molecules, but in 
contrast to CTLs that become licensed to kill by recognizing specific antigens 
presented on self-MHC I molecules, NK cells identify and kill cells with no or 
low levels of these molecules (Ljunggren 1990). As an attempt to circumvent T 
cell detection, tumor cells and virus infected cells have been shown to down-
regulate their MHC I expression (Lanier 2005). Consequently, by this adaption 
they instead become possible targets for NK cell mediated killing. NK cells also 
express inhibitory MHC I receptors which, upon ligation, block NK cytotoxicity 
(Karlhofer 1992; Moretta 1993). 
CD1d-restricted NKT cells are classically defined as innate-like lymphocytes 
that similar to NK cells exert cytotoxic activity and may kill target cells without 
prior sensitization. Both exogenous and endogenous glycolipid antigens may be 
presented on CD1d molecules and have been shown to activate NKT cells 
during microbial infections (Mattner 2005). 
Innate lymphocytes as accessory cells during DC maturation 
NK and NKT cells sense infections and cellular transformation via receptors 
other than TLRs. These recognition mechanisms are now being placed into the 
context of DC biology and it has been proposed that the interaction of DCs with 
these innate lymphocytes represents a major control mechanism for immunity 
that is independent of TLR ligands (Munz 2005). DC maturation has been 
documented in vitro and in vivo after NK cell recognition of MHC class I
low
 
tumor cells (Mocikat 2003) and NKT cell stimulation by the synthetic 
invertebrate glycolipid α-galactosylceramide (α-GalCer) presented on DC CD1d 
molecules (Fujii 2002; Hermans 2003). In line with this data, the reciprocal 
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interaction of CD1d-restricted NKT cells and DCs has been shown to induce a 
cellular activation cascade involving elements of innate and adaptive immunity 
that may lead to anti-tumor immunity (Carnaud 1999). 
After activation, NK as well as NKT cells are able to induce DC maturation as 
evidenced by increased expression of CD86, IL-12 production and priming of T 
cell responses. TNF has been identified as a crucial inducer of DC maturation in 
these studies (Fernandez 1999; Gerosa 2002; Fujii 2004). In addition, CD40–
CD40L interactions induced by NKT cells allowed for priming of adaptive 
immune responses by DCs (Fujii 2004). Thus, NK and NKT cells are able to 
induce DC maturation by a combination of cytokine- and cell contact–dependent 
signals.  
Recent data, from mouse models demonstrate that NK cells are recruited to 
lymph nodes in a CXCR3-dependent manner after infection or immunization. 
These NK cells exert helper functions by providing an early source of IFN- that 
is central for Th1 polarization (Martin-Fontecha 2004; Bajenoff 2006). 
The interaction of NKT cells with antigen-capturing DCs likewise allows for the 
induction of antigen-specific, Th1-polarized T cell responses (Fujii 2004). Thus, 
both NK and NKT cells may act as helper cells that assist DC-induced Th1-
deviated adaptive immune response.  
Finally, NK and NKT cells can also provide antigenic material for DCs. 
Fragments of infected cells or tumor cells, generated during the destruction of 
target cells by these innate lymphocytes, are taken up by DCs and displayed on 
MHC molecules, thus eliciting an adaptive T cell response in vivo (Mocikat 
2003). 
IMMUNITY AND CANCER 
Tumor cells express unique, potentially immunogenic antigens that can be 
processed and presented by DCs as tumor-specific peptide-MHC complexes and 
thereby be recognized by the T cell repertoire. The question is, how can 
potentially immunogenic tumors develop in the presence of an intact immune 
system?  
For this purpose, tumor cells have been shown to develop different mechanisms 
to escape host immunity. Tumor-specific antigens are in general not strongly 
immunogenic, and in combination with tumor-produced immunosuppressive 
factors, such as prostaglandins that are known to reduce MHC II and co-
stimulatory molecule expression on DCs, this generates DCs that show impaired 
ability to deliver signal 1 and 2 (Gabrilovich 2004; Melief 2008). Insufficient 
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antigen presentation and co-stimulation may induce anergy and apoptosis in 
tumor-specific T cell populations (Steinman 2003) 
Prostaglandins can also suppress NK cell activity, suppress the functions of Th1-
deviated immunity (Snijdewint 1993; Hilkens 1995; Kalinski 1997; Kalinski 
2001) and prime DCs for elevated Treg and Th2 cell recruitment (Lebre 2005; 
McIlroy 2006; Muthuswamy 2008). Other ways in which tumor cells may 
escape the attention of sensitized tumor-specific T cells are by down regulating 
MHC I and producing TGF-β that suppress CTL activation (Gabrilovich 2004; 
Li 2006). Furthermore, production of TGF-β and IL-10 can together induce the 
maturation of different Treg subsets (Jarnicki 2006).  
Additionally, essential for the development and maintenance of this tumor 
protective, immunosuppressive microenvironment is the recruitment of tumor-
associated macrophages, myeloid-derived suppressor cells (Marigo 2008) and 
regulatory T cells (Wing 2008). All together this creates a complex network of 
cells that support tumor expansion both locally at the tumor site and in lymphoid 
organs where antigen presentation and polarization of adaptive immunity occurs.    
CHRONIC LYMPHOCYTIC LEUKEMIA 
Chronic lymphocytic leukemia (CLL) is the most common form of leukemia in 
Western countries and primarily affects the elderly. The median age at diagnosis 
is 72 years and CLL is rarely seen in people younger than 40 (Jemal 2009). CLL 
is a clonal malignancy of B lymphocytes and, with regard to the latest WHO 
classification scheme, considered a mature B cell neoplasm (Swerdlow 2008). 
The disease is usually indolent and is characterized by a slowly progressive 
accumulation of long-lived small B cells in blood, bone marrow, lymph nodes or 
lymphoid tissue. In time bone marrow failure could occur that affects the 
development and function of all types of blood cells (Zenz 2010). Despite 
advances in understanding the pathogenesis and therapy development, the 
reason for the abnormal expansion of malignant cells is still unknown and CLL 
remains incurable with conventional therapies. 
Diagnosis 
To diagnose CLL the presence of more than 5x10
9
/L clonal B cells in the 
peripheral blood is required (Hallek 2008). Furthermore, flow cytometry is used 
to confirm the clonality and phenotype of the circulating B cells. Each clone of 
CLL cells expresses either kappa or lambda Ig light chains (Moreau 1997). CLL 
cells can phenotypically be characterized by the co-expression of the B cell 
markers CD19, CD20, CD23 and the T cell marker CD5 (Hallek 2008). The 
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expression of the surface phosphoprotein CD20 is generally low when compared 
to normal B cells (Moreau 1997). 
Prognosis and staging of CLL 
CLL is extremely heterogenous with regard to its clinical course and there are 
patients that live for decades with no or only marginal need for treatment, while 
others have a rapidly aggressive clinical course and may die within a couple of 
years despite aggressive therapy with multiple chemotherapy agents. There are 
two clinical staging systems, Binet and the Rai, used for prognostic purpose. 
Both classifications are based on simple and robust clinical parameters, but there 
are still significant differences in the disease course of the individual patient. 
Instead, in recent years cytogenetic changes and mutation status of the 
immunoglobulin heavy chain variable (IGHV) genes have been shown to better 
identify the progression risk of the individual patient (Van Bockstaele 2009). 
Treatment of CLL 
As CLL is generally considered incurable, the main focus when treating CLL is 
not to cure, but rather to control the disease and its symptoms. Detailed 
discussions of all the different treatments and drugs used in CLL are beyond the 
scope of this thesis, but some are mentioned below and those of importance for 
this thesis are described in more detail. 
The initial treatment of choice is often a combination of chemotherapeutic 
agents, sometimes in combination with passive immunotherapy, such as 
monoclonal antibody-targeted therapies (i.e., the anti-CD20-antibody rituximab) 
(Hallek 2010). Currently, the only curative approach for CLL is allogeneic stem 
cell transplantation (alloSCT). However, due to the high risk of treatment-
related morbidity and mortality associated with alloSCT, for the majority of 
patients this is not an available option (Michallet 1991; Schetelig 2003; Sorror 
2008). Also, the outcome after alloSCT is strongly dependent on a series of risk 
factors, including patient age and the phase of the disease (Michallet 1991; 
Schetelig 2003; Sorror 2008). 
Irrespective of the negative side effects, immunological observations and the 
strong anti-tumor response seen after alloSCT suggest a possible immune- 
mediated cure for CLL. Therefore, alternative and less aggressive 
immunotherapeutic approaches, including active immunization strategies, may 
potentially be used. In addition, the absence of a rapidly progressive disease and 
the generally indolent clinical course of CLL may also facilitate immunization 
regimens.  
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DENDRITIC CELLS IN CANCER IMMUNOTHERAPY 
The idea of utilizing the unique immune-modulating capacity of DCs in the 
context of cancer treatment is not new. The discovery that a large number of 
human DCs easily can be produced from monocytes isolated from peripheral 
blood formed the basis for the expanding field of therapeutic cancer vaccines 
(Sallusto 1994).  
Ex vivo-generated vaccine DCs do not have a direct tumor-killing activity, 
which is the case for chemotherapy and adoptive (passive) immunotherapies 
with antibodies or ex vivo-expanded tumor-specific T cells. Instead DC-based 
vaccines aim to reset a patient’s immune system and thereby elicit anti-tumor 
responses in vivo. The general idea with this immunotherapeutic strategy is to 
optimize antigen presentation and activation of monocyte-derived autologous 
DCs ex vivo in a non-suppressive environment. Hypothetically, assuming 
optimal maturation conditions and source of tumor antigens, when adoptively 
transferred back to the patient, these vaccine DCs should traffic to the draining 
lymph node and induce effective type-1 polarized anti-tumor immune responses 
(Mempel 2004).  
Multiple strategies have been used to induce maturation of DCs and to introduce 
antigens into potential DC-based cancer vaccines both in animal models and in 
humans. In murine models, vaccine DCs that have been pulsed with tumor 
lysates or peptides, transfected with RNA or DNA encoding tumor antigens, or 
fused to tumor cells, have been shown to induce promising and sometimes 
protective tumor-specific immunity (Gilboa 2007; Melief 2008). Although DC-
based vaccines have been effective in animal models, the
 
immune responses 
observed after DC-based vaccines in humans are often weak, and clinical
 
responses are rarely complete and long lasting. This insufficient response in 
humans may be due to various factors, such as administration of DCs with 
unsuitable maturation state and Th1-deviating capacity, relatively low cell 
numbers, inappropriate vaccination route or frequency of injections (Melief 
2008). 
Dendritic cell-based cancer vaccines and delivery of signal 1, 2 and 3 
A key challenge when considering active immunotherapy against cancer is to 
find out how to develop optimally matured vaccine cells with potent 
immunostimulatory functions, strong enough to overcome the immune 
suppressive state characteristic for cancer patients. The traditional view of such 
a favorable vaccine DC is based on what we know about DCs as key players in 
inducing efficient elimination and long lasting memory to intracellular bacterial 
and viral infections. The activated DCs must first of all have lymph node 
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homing potential. On arrival, they have to provide naïve T cells with antigen-
specific signal 1, co-stimulatory signal 2 and also to be functionally mature in 
order to deliver the Th1-polarizing signal 3 (Schuler 1997; Banchereau 1998; 
Kalinski 1999; Vieira 2000; Schuler 2003). 
The first clinical pilot studies involving active immunotherapy were performed 
in the 1990s in B-cell lymphoma and malignant melanoma and the vaccine cells 
used in these studies were relatively immature DCs (Hsu 1996; Nestle 1998). 
Promising results, such as stabilization and cancer regression, were observed but 
only in a proportion of patients. This first generation of relatively immature DC-
based vaccines has in general been attributed to impaired lymph node homing 
capacity (Dhodapkar 1999; de Vries 2003). Vaccine DCs, solely activated with 
TNF-α, were recently evaluated in two clinical trials in CLL (Hus 2005; Hus 
2008). However, the results were similar to those obtained for immature DCs, 
showing a relatively modest clinical effect despite a measurable induction of 
tumor-specific CTLs.  
The second generation of DC-based vaccines, matured with a “gold standard” 
maturation cocktail, consisting of TNF-, IL-1, IL-6 and prostaglandin-E2 
(PGE2) (Jonuleit 1997), have been the most frequently used vaccine DCs to date. 
These PGE2DCs show a fully mature phenotype and are able to present tumor 
antigen as well as appropriate co-stimulatory molecules (signal 1 and 2). Signals 
provided by PGE2 were further shown to induce high expression of CCR7 that 
made them superior at migrating towards lymphoid chemokines when compared 
to first generation DC vaccines (Luft 2002; Scandella 2004).  
As with first generation DC vaccines, there is clinical data indicating that PGE2-
matured DCs may also be insufficient for cancer treatment: a phase III trial in 
patients with malignant melanoma failed to show the advantage of PGE2DCs 
over standard dacarbazine chemotherapy (Schadendorf 2006). Furthermore, 
PGE2DCs were recently shown to be even more effective than immature DCs at 
inducing Treg expansion in vitro and in vivo in myeloma patients (Banerjee 
2006). These observations underscore the difficulty in generating tumor 
regression in patients treated with PGE2-matured DCs. The main reason for the 
drawback with PGE2DCs is most likely their impaired IL-12p70 production 
upon CD40 ligation (lack of a Th1-polarizing signal 3) (Kalinski 1999; Lee 
2002). This further emphasizes that other aspects besides phenotypic maturation 
must be taken into account when designing new DC-maturation protocols.  
The main objective with current DC-maturation protocols has been to find a 
vaccine DC candidate that combines a fully mature phenotype (lymph node 
homing potential and delivery of signal 1 and 2) with the capacity to produce IL-
12p70 and thereby deliver a Th1-polarizing signal 3, known to be important for 
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anti-tumor immunity. Since IFN- has been shown to facilitate the production of 
IL-12p70 by DCs primed by microbial products or inflammatory cytokines such 
as TNF- and IL-1 (Vieira 2000), the addition of IFN- to the standard PGE2-
containing maturation cocktail was recently evaluated. However, the addition of 
IFN- was shown to inhibit membrane expression of CCR7 and reduced 
migration of DCs towards lymph node chemokines (Alder 2006).   
A new DC vaccine candidate, first described by Mailliard et. al (Mailliard 2004) 
seems to express all the key features classically ascribed a Th1-polarizing DC. 
They reported that the inclusion of IFN- and the TLR3 ligand 
polyinosinoine:polycytidylic acid (p-I:C) to the “original” IL-12p70-inducing 
cytokine cocktail, composed of TNF-, IL-1 and IFN- (Vieira 2000), 
generated DCs with high migratory function towards lymph node chemokines 
combined with a strong ability to produce IL-12p70. A recent in vitro study 
demonstrated that such “-type-1 polarized DCs” (DC1s) and non-polarized 
PGE2DCs induced similar CD8
+
 T cell expansion, but only αDC1s were able to 
induce functional CTLs with cytolytic function and tumor relevant homing 
capacity (Watchmaker 2010). 
In vivo activation of endogenous APC in DC-based cancer vaccination 
There are still many pieces missing in our understanding of the complex puzzle 
of sequential events that occurs after injection of ex vivo generated vaccine DCs.  
Contrary to the classical view, autologous DC-based vaccines were recently 
shown to have a minor role in the direct priming of antigen-specific T cells in 
vivo. Instead, it was suggested that they indirectly prime naïve CD8
+
 T cells by 
acting as an immune adjuvant that transfers antigens to locally recruited 
endogenous APCs (Yewdall 2010). Similar observations have been reported 
after injection of allogeneic vaccine DCs. Results from these mouse studies have 
shown that fully allogeneic vaccine DCs loaded with viral or tumor antigens are 
able to induce a robust cross-priming of cytotoxic T lymphocytes (CTLs) 
(Racanelli 2004; Edlich 2010). 
These observations were further supported by recent data from migration studies 
on human monocyte-derived autologous vaccine DCs after intradermal injection 
(Verdijk 2009). Interestingly, despite the presence of PGE2 during ex vivo 
maturation, the majority of DCs remained at the injection site, and less than 5 % 
of the injected DCs reached the draining lymph nodes. Vaccine DCs that were 
trapped at the injection site rapidly lost their viability and were cleared by 
recruited antigen-presenting cells within 48 hours.  
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Taken together, unlike the features classically ascribed an optimal DC-based 
vaccine, these data indicate that autologous as well as allogeneic vaccine DCs, 
could play a crucial role as pure immune adjuvants. From this point of view, to 
be efficient, the tumor-loaded vaccine DCs that are trapped at the injection site 
must attract and directly or indirectly activate endogenous DC-precursors. 
Assuming proper activation, these recruited DC-precursors may, after 
engulfment of relevant antigens from dying vaccine cells and migration to 
lymph nodes, induce Th1-polarization leading to tumor rejection. 
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GENERAL AIM 
The overall aim of this thesis was to evaluate if different in vitro culture 
conditions, used to generate clinical grade DC-based cancer vaccines, 
differentially imprint certain functions in DCs that are essential for their ability 
to induce type-1 polarized, anti-cancer immune responses. 
SPECIFIC AIMS: 
 to evaluate if the ability of DC-based cancer vaccine to recruit and 
activate preferable Th1-associated lymphocyte subsets can be differently 
imprinted during DC maturation by the “standard” cocktail (IL-1β/TNF-
α/IL-6/PGE2) and α-type 1-polarized DC cocktail (IL-1β/TNF-α/IFN-
α/IFN-γ/poly-I:C)  
 
 to examine if functional autologous DC-based cancer vaccines with a 
desirable chemokine/cytokine profile and lymphocyte attracting ability 
can be generated from CLL patients  
 
 to compare the ability of allogeneic PGE2DCs and αDC1s to recruit 
monocytes and different subsets of potential accessory cells from CLL 
patients, and to investigate if the conditions induced by these allogeneic 
vaccine DCs support the maturation of recruited monocytes toward 
desirable Th1-deviating DCs 
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METHODOLOGICAL CONSIDERATIONS 
Detailed descriptions on the experimental procedures are given in the individual 
papers. The following section contains an overview and general description of 
some methods of particular importance for this thesis.  
PATIENTS AND HEALTHY BLOOD DONORS 
After gaining informed consent, peripheral blood was collected from healthy 
blood donors and CLL patients. The study protocol was approved by the Human 
Research Ethics Committee at the Sahlgrenska Academy, University of 
Gothenburg. Patients enrolled to paper II and III were untreated, stable CLL 
patients, all in Binet stage A, diagnosed at the Section of Hematology and 
Coagulation at Sahlgrenska University Hospital, Gothenburg, Sweden. The 
diagnosis of CLL was based on WHO criteria at the time of inclusion 
(Swerdlow 2008). 
CELL SEPARATION AND DENDRITIC CELL MATURATION 
The pioneering work of Sallusto and Lanzavecchia in the mid-1990s 
demonstrated that DCs can be cultured ex vivo from human blood monocytes 
using GM-CSF and IL-4 (Sallusto 1994). These observations initiated the era of 
ex vivo generated human DC-based vaccines and since then this has become the 
most commonly used protocol for in vitro generation on DCs. The procedure 
used in this thesis for cell isolation and generation of monocyte-derived DC 
vaccine cells is described below. 
Density gradient centrifugation was used to isolate peripheral blood 
mononuclear cells (PBMC) from heparinised peripheral blood obtained from 
healthy donors or CLL patients. This is an effective and simple cell separation 
method that was first described by Dr. Arne Bøyum in 1968 (Boyum 1968). The 
technique is based on the fact that mononuclear cells (monocytes and 
lymphocytes) have a lower density than the erythrocytes and the 
polymorphonuclear leukocytes (granulocytes). The PBMCs can thereby be 
isolated by centrifugation on a separation medium with a density just above the 
majority of mononuclear cells. This allows the erythrocytes and the granulocytes 
to sediment through the medium while the mononuclear cells are concentrated 
as bands at the sample/medium interface where the cell density matches that of 
the surrounding solution. 
Monocytes were then separated from the PBMC population either by plastic 
adherence (paper I) or with CD14
+
 magnetic beads (paper I, II, III). When 
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plastic adherence was used for monocyte isolation, non-adherent cells were 
removed after 2 hours. Cell isolation with magnetic beads was frequently used 
throughout this study. In brief, PBMCs were incubated with magnetically 
labeled antibodies and labeled cells were subsequently collected or removed 
using a magnetic field. This technique allows a rapid depletion of unwanted 
cells or collection of fairly pure populations of desired cell types. 
Monocytes from CLL patients were isolated from lymphocytes with a second 
gradient centrifugation followed by isolation with CD14
+ 
magnetic beads (paper 
II, III). This was done to get rid of the main proportion of the contaminating 
malignant B cells that constitute around 70 % of the PBMC population in the 
untreated, stable CLL patients that were enrolled in this study. Irrespective of 
the isolation protocol, the remaining population of PBMCs depleted of CD14
+
 
monocytes were often saved for later use as relevant responder cells (circulating 
blood lymphocytes) during co-culture experiments with vaccine DCs. 
Monocytes were cultured in clinical grade serum-free culture medium 
supplemented with recombinant human GM-CSF and IL-4 (R&D Systems) for 5 
days, in order to obtain immature DCs. During the last 24 hours of culture, DC 
maturation was induced by supplementing the culture media with various 
maturation stimuli. Immature DCs cultivated without addition of any maturation 
cocktail were used as controls. In paper II the possible negative impact of 
loading vaccine DCs with relevant tumor antigens were studied. For this purpose 
DCs were pulsed with heat stressed, necrotic CLL cells at a ratio of 1:1 at the 
same time as the maturation-inducing cytokines were added. In all 3 papers two 
different maturation cocktails were used and compared; the gold standard 
maturation cocktail for DC-vaccines (TNF-α, IL-1β, IL-6 and PGE2) (Jonuleit 
1997), and the αDC1-maturation cocktail (IFN-α, IFN-γ, TNF-α, IL-1β and 
poly-I:C) (Mailliard 2004).  
In paper I, monocytes were cultured in AIM-V medium (Invitrogen) and in 
paper II and III AIM-V, was replaced by CellGro DC medium (CellGenix). The 
medium was substituted as a result of repeated observations of changes in DC 
behaviors and morphology that, for some unaccountable reason, occurred when 
new batches of AIM-V medium were used. Changes, such as increased 
adherence, complicated the collection of cells and resulted in lower rates of cell 
recovery. This phenomenon was especially pronounced in cultures of αDC1s 
and therefore recovery rates of this vaccine type was much lower than for 
loosely adherent PGE2DCs. This problem was solved by substituting the AIM-V 
with CellGro DC medium. αDC1s generated in this new medium were smaller 
and just as loosely adherent as PGE2DCs, which resulted in similar cell recovery 
when cells were harvested. Similar observations were recently reported by 
others. In the study performed by Lee et al. a 30% lower recovery rate of 
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αDC1s, compared with PGE2DCs were observed in cultures performed in AIM-
V medium (Lee 2008).   
CYTOKINE AND CHEMOKINE DETERMINATION BY ELISA 
Enzyme-linked immunosorbent assay (ELISA) was used to detect the amount of 
cytokines and chemokines released into culture supernatants of vaccine DCs 
alone or in co-culture with various responder cell populations (paper I, II, III). In 
basic terms, a plate is coated with a capture antibody specific to the analyte of 
interest. Samples or standards are then added and any analyte present will bind 
to the immobilized antibody. In the next step, a conjugated detecting antibody 
(e.g. biotin conjugated), which binds to the analyte, is included. An enzyme-
linked detection reagent (e.g. streptavidin-HRP) is then added. This binds to the 
conjugate. Finally, a substrate solution (e.g. TMB/hydrogen peroxide) is added 
to activate the enzyme and convert the substrate to a coloured product. The color 
develops in proportion to the amount of analyte present in the added sample. 
The quantity of analyte is measured as absorbance.   
FLOW CYTOMETRY 
Flow cytometry was used to evaluate phenotypic DC maturation induced by 
different stimuli, and to quantify the migration of different leukocyte subsets in 
response to chemokine gradients created by vaccine DCs. Flow cytometry was 
also used for evaluation of the interaction between NK cells with vaccine DCs 
as determined by expression of CD69 and intracellular IFN-γ.  
This technique is also routinely used in the diagnosis of leukemias. Briefly, cells 
were collected and cell suspensions were incubated with fluorescently labelled 
antibodies specific for numerous different markers that enabled the 
identification of cell subsets by flow cytometry.  
Flow cytometry is designed for quantification and sorting of microscopic 
particles, such as cells. By passing the cells one by one in a stream of fluid 
through a light beam in the apparatus, physical and fluorescent characteristics of 
individual cells can simultaneously be detected. Every cell that passes through 
the laser light scatters the beam differently depending on size and granularity, 
simultaneously the fluorescently-labelled antibodies attached to each cell 
become excited and emit fluorescent light which is measured using appropriate 
filters. A number of detectors, specialized at detecting such fluorescent or 
scattered light, are placed to encircle the site where the stream passes through 
the light beam. One of the detectors is denoted Forward Scatter (FSC) and 
placed in line with the laser beam from where it detects the size of the cell as it 
passes through the beam. Other detectors are arranged vertical to the stream, 
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such as various numbers of fluorescent detectors and a Side Scatter (SSC) 
detector that distinguish the granular content of the cells.  
The acquired data can be analyzed and plotted in a single dimension, producing 
a histogram, or in two-dimensional dot plots or density plots. Depending on the 
fluorescence intensity, correlating with the expression of a specific marker, the 
cells will cluster into certain regions on these plots. Cell populations can then be 
further separated by creating a series of electronic “gates” allowing detailed 
analysis of the cell subsets of interest.  
MIGRATION ASSAYS 
Migration assays were used to predict the capacity of different DC vaccines to 
recruit specific subsets of leukocytes of importance for efficient Th1-deviating 
ability. This method was included in all the three papers and depending on the 
purpose, slightly different setups were used.  
In general terms, migration of monocytes and lymphocytes towards chemokines 
produced by differently matured vaccine DCs was evaluated in two different 
transwell assays (chemotaxis and migration assays). In brief, purified monocytes 
from healthy donors (papers I and III) or CLL patients (paper II) were cultured 
with GM-CSF and IL-4 for 5 days. At day 4, immature DCs were matured with 
either the αDC1 or the PGE2DC maturation cocktail for 24 hours, then washed 
twice and replaced in fresh medium. Unstimulated DCs were used as immature 
controls. These different DC subsets or their secreted inflammatory mediators in 
the culture supernatants were then used in the chemotaxis or migration assays. 
In paper I, a transwell assay was used to study chemotaxis of NK cells toward 
chemokines produced by vaccine DCs generated from healthy blood donors. In 
this experiment, culture supernatants collected from previously washed and 
mature or immature DCs were added the lower chambers of transwell plates. 
Medium only was used as a control to determine spontaneous fallout. PBMCs or 
purified NK cells were added to the upper chamber and the plate was incubated 
for 90 min. Cells that migrated to the lower chamber were harvested and stained 
with fluorescently labelled antibodies specific for CD56 and CD3. CD3
−
CD56
+
 
NK cells were subsequently defined and counted by flow cytometry. 
In paper II, a migration assay was used to study migration of NK and NKT cells 
toward chemokines produced by tumor-loaded vaccine DCs generated from 
CLL patients. This migration model was aimed to more closely mimic in vivo 
conditions whereby cells in the upper chamber had to actively migrate along 
gradients of chemokines through an artificial cell layer composed of matrigel 
marix. Culture supernatants collected from previously washed and mature or 
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immature DCs were added to the lower chambers of transwell plates. PBMCs 
isolated from CLL patients were partly depleted of B cells with CD19
+
 magnetic 
beads before they were added to the upper chambers. The plate was incubated 
for 24 hours. Cells that migrated to the lower chamber were harvested and 
stained with fluorescently labelled antibodies specific for CD5, CD56, HLA-
DR, CD3 and CD45. CD3
-
CD56
+
 NK cells and CD3
+
CD56
+
 NKT cells were 
subsequently defined and counted. 
In paper III, a chemotactic transwell assay was used to evaluate the chemotaxis 
of monocytes and different lymphocyte subsets towards chemokines produced 
by differently matured tumor-loaded allogeneic vaccine DCs generated from 
healthy blood donors. Unlike paper I and II, in which supernatants were added 
to the lower chambers, in paper III the vaccine cells were cultured directly in 
lower chambers of transwell plates and after 24 hours of maturation, the DCs 
were washed and replaced in fresh medium for a further 24 hours (a similar 
procedure to that in paper I and II but in paper III no supernatants were 
collected). PBMCs isolated from CLL patients were partly depleted of B cells 
(as in paper II). After 24 hours incubation, PBMCs isolated from CLL patients 
were added to the upper chamber and the plate was incubated for 90 min. 
Migrated monocytes were distinguished from vaccine DCs by pre-labeling 
PBMCs from CLL patients with fluorescent cell linker dyes (PKH2). This 
technique provides a non-specific cell membrane labeling of live cells over an 
extended period of time. For quantification of migration, the cells that migrated 
to the lower chamber were harvested and stained with fluorescently labelled 
antibodies specific for CD14, CD4, CD8, CD56 and CD3. CD14
+
PKH2
+
 
monocytes, CD3
-
CD56
+
 NK cells, CD3
+
CD56
+
 NKT cells, CD3
+
CD8
+
 T cells 
and CD3
+
CD4
+
 T cells were subsequently defined and counted.  
CO-CULTURE SYSTEMS  
Various co-culture systems, often referred to as mixed leukocyte reactions 
(MLRs) were used to study the interaction of vaccine DCs and different 
subpopulations of leukocytes. The combination of these different experimental 
systems were intended to give an insight into some key mechanisms in the 
sequence of events that may occur following injection of vaccine DCs into a 
cancer patient.   
A model to mimic DC-NK cell interactions in lymphoid organs 
In paper I, co-culture experiments were performed to study the potential of 
differentially matured vaccine DCs, generated from healthy blood donors, to 
induce “helper” NK cell activation, determined by intracellular IFN-γ, which 
was recently suggested to assist DC-mediated Th1 polarization (Martin-
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Fontecha 2004). Therefore, to mimic the in vivo situation where subcutaneously 
injected autologous DCs first have to migrate to draining lymph nodes, 
previously washed mature vaccine DCs were cultured in fresh medium for a 
further 24 hours, before co-culturing with non-adherent PBMCs (PBMC/DC 
ratio, 5:1). Co-cultures were performed in the presence of brefeldin A, a product 
that inhibits transport of proteins (i.e. IFN-γ) from ER to Golgi and which leads 
to protein accumulation inside the ER. DCs used in this experiment had 
previously been stimulated with either the PGE2DC or the αDC1 maturation 
cocktail for 24 hours. After 6 hours of subsequent co-culture, the cells were 
harvested. To allow detection of intracellular IFN-γ, a fixation/permeabilization 
procedure was performed before fluorescently labelled antibodies specific for 
IFN-γ, CD56, CD3, and the NK cell activation marker CD69, were added. 
Activation of CD3
-
CD56
+
 NK cells was analyzed by flow cytometry.  
A model to mimic potential vaccine DC-T cell interactions in lymphoid 
organs 
In paper II, an artificial co-culture system was used to study the ability of 
differentially matured vaccine DCs generated from CLL patients to secrete Th1-
polarizing IL-12p70 upon CD40 ligation. The system was also used to evaluate 
their production of the chemokines CCL3/MIP-1α and CCL4/MIP-1β which 
have been shown to play a crucial role in recruitment of CD8
+
 T cells to sites of 
DC-CD4
+
 T cell interactions (Castellino 2006). DCs used in this experiment 
were pulsed with heat stressed, necrotic CLL cells and left immature or 
stimulated with either the PGE2DC or the αDC1 maturation cocktail for 24 hours 
before being washed twice, replaced in the well and cultured in fresh medium 
for a further 24 hours. Mature DCs were stimulated with soluble, histidine-
tagged, CD40 ligand followed by the addition of anti-polyhistidine monoclonal 
antibody. This procedure was aimed to mimic the interaction of a potential 
vaccine DC with CD40L-expressing cells, such as CD4
+ 
T cells and NKT cells 
at lymph node entry. Supernatants were collected after 24 hours and tested for 
the presence CCL3/MIP-1α, CCL4/MIP-1β and IL-12p70 by ELISA.  
Selective allogeneic MLR to mimic immune responses at the injection 
site  
The experimental systems used in paper III were designed to mimic the in vivo 
situation, where allogeneic vaccine DCs must recruit favorable subsets of 
leukocytes which assist in the generation of a pro-inflammatory milieu at the 
injection site that is of importance for proper activation of co-recruited 
endogenous DCs. The chemotaxis transwell assay described earlier was also 
used to study the production of the proinflammatory cytokine IFN-γ induced in 
“selective” MLRs of differentially matured allogeneic vaccine DCs and 
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recruited PBMCs isolated from CLL patients. As previously described 
monocyte-derived immature DCs from healthy donors were cultured in lower 
chambers of 24-(trans)well plates, pulsed with heat stressed, necrotic CLL cells 
and matured with either the αDC1 or PGE2DC maturation cocktail for 24 hours 
before being washed and replaced in fresh medium. Unstimulated DCs were 
used as immature controls. After 24 hours incubation, PBMCs isolated from 
CLL patients and partly depleted of B cells, were added to the upper chamber. 
After 90 min incubation, all inserts were removed and the plate was incubated 
for a further 24h. Thereafter, supernatants from these selective MLRs were 
collected and the concentration of IFN-γ was measured by ELISA. Supernatants 
from selective MLRs were also used in functional assays for the maturation of 
monocytes, representing in vivo recruited “bystander” monocytes. 
Phenotypic maturation of bystander monocytes 
The above described assay was also used to study the phenotypic maturation of 
recruited bystander monocytes (paper III). Migrated PKH2-labelled monocytes, 
matured in the microenvironment created by differentially matured allogeneic 
DCs and recruited lymphocytes for 24h, were analyzed for the presence of DC 
maturation markers. Cells were stained with fluorescently labelled antibodies 
specific for CCR7, CD40, CD83, CD86, and analyzed by flow cytometry.  
Evaluation of functional maturation in bystander monocytes  
The Th1-deviating capacity of bystander DCs was studied in a Staphylococcus 
Enterotoxin B (SEB)-driven model (paper III). SEB is a superantigen that has 
been used as a surrogate antigen in different in vitro models (Mailliard 2002), as 
it allows stimulation of a high proportion of autologous CD4
+
 and CD8
+
 T cells 
by cross-linking MHC molecules on DCs and TCRs expressing the appropriate 
Vβ chains (Fraser 1989). Functional maturation of bystander monocytes was 
evaluated by culturing monocytes isolated from CLL patients in selective MLR 
supernatants from differentially matured allogeneic vaccine cells and migrated 
PBMCs. Monocytes were plated in 24-well plates. After 24 hours stimulation, 
the cells were washed and replaced in fresh medium for a further 24 hours. This 
was done in order to mimic the in vivo situation, where endogenous DCs that 
phagocytose dying vaccine cells at the injection site first have to migrate to 
draining lymph nodes to induce polarized adaptive immune responses. The next 
step of this system was aimed to simulate cell interactions that may occur when 
endogenous DCs reach a draining lymph node. Following 24 hours incubation, 
activated bystander monocytes/DCs were coated with SEB followed by the 
addition of autologous PBMCs depleted of monocytes and partly depleted of B 
cells. After 6 days of co-culture, Th1-deviation was estimated by using ELISA 
to determine the production of the typical Th1 cytokine IFN-γ and the typical 
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Th2 cytokines IL-4 and IL-5 in these primary autologous MLR supernatants. 
The Th1-deviating capacity of  bystander DCs was further studied by re-
stimulating  previously washed PBMCs, collected from different primary MLR 
cultures, with autologous SEB-coated CLL cells. After 24 hours of re-
stimulation, supernatants were collected and the production of IFN-γ, IL-4 and 
IL-5 was evaluated. 
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RESULTS AND DISCUSSION 
PAPER I 
Sallusto and colleagues convincingly demonstrated using a mouse model that 
the chemokine receptor CXCR3 has a central role in lymph node–homing 
properties of NK cells on stimulation by injected mature DCs or certain 
adjuvants and further that these recruited NK cells provide an early source of 
IFN-γ that is necessary for Th1 polarization (Martin-Fontecha 2004; Bajenoff 
2006). This unique function demonstrated by certain adjuvants implies that for 
vaccines that depend on Th1 responses, adjuvants could be selected according to 
their ability to recruit NK cells into antigen-stimulated lymph nodes. With 
regard to this important finding, the aim of paper I was to compare the ability of 
second generation PGE2DC-vaccines and the new vaccine candidate DC1s to 
selectively produce favorable chemokines such as CXCR3 ligands and to recruit 
and activate human NK cells in vitro.  
αDC1s but not PGE2DCs produce desirable chemokines of importance 
for  NK cell recruitment  
Our data show that αDC1s generated from healthy blood donors secrete profuse 
amounts of the CXCR3 ligand CXCL9/MIG and also substantial amounts of 
CXCL10/IP-10 and CXCL11/I-TAC after withdrawal of maturation stimuli, that 
is at the point in time when they are ready to be injected. In contrast, no 
measurable levels of the CXCR3 ligands were produced by PGE2DCs (paper I 
figure 2a).   
It has become clear that a major challenge in the development of a successful 
tumor vaccination method is to avoid the recruitment of suppressive Tregs to 
sites of antigen-specific DC-T cell interactions within vaccine-draining lymph 
nodes that could hinder optimal activation. In paper I we found that PGE2DCs 
generated from healthy blood donors preferentially produced Th2 and Treg- 
recruiting CCL17/TARC and CCL22/MDC (Bonecchi 1998; Iellem 2001), 
whereas only marginal levels of these chemokines were produced by αDC1s 
(paper I figure 2b).  These findings are further supported by recent data from 
Muthuswamy et al. demonstrating in vitro that such monocyte-derived 
PGE2DCs produced CCL22/MDC that efficiently attracted FOXP3
+ 
Tregs 
(Muthuswamy 2008). It was concluded that the ability of mature DCs to interact 
with Treg cells was predetermined at the stage of DC maturation, as the CCL22 
producing capacity by PGE2DCs persisted after the removal of maturation 
stimuli and was further elevated after secondary stimulation of DCs in a neutral 
environment. 
RESULTS AND DISCUSSION 
 
37 
 
αDC1s show an increased NK cell recruiting capacity compared to 
PGE2DCs  
Results from chemotactic transwell experiments show that supernatants 
collected from previously washed αDC1s, but not from PGE2DCs, induced a 
substantial recruitment of NK cells. We evaluated the possibility that the 
extremely high level of CXCL9 in supernatants from αDC1s was primarily 
responsible for the observed NK cell recruitment. When anti-CXCL9 antibodies 
were added to the αDC1 supernatants, a marked reduction of NK cell migration 
was observed (paper I figure 4). This novel feature of αDC1s, such as high and 
sustained production of the NK cell–recruiting CXCR3 ligands correlating with 
functional NK cell recruitment, thus indicates a potential NK cell–recruiting 
capacity into draining lymph nodes when injected into human patients. 
Helper cell requirement for autologous αDC1-induced IFN-γ 
production by NK cells  
In line with recent data from different mouse models (Martin-Fontecha 2004; 
Bajenoff 2006), our in vitro data demonstrate that NK cells became activated on 
interaction with DCs. However, only αDC1s were able to induce a substantial 
IFN-γ production, as determined by flow cytometry (paper I figure 5a). 
Furthermore, when compared with PGE2DCs, αDC1s proved superior in 
inducing up-regulation of CD69, which is an inducible cell surface protein that 
first appears during NK cell activation. The observed activation of NK cells 
within bulk lymphocyte fractions, induced by co-cultured αDC1s, was 
dependent on co-factors expressed by lymphocytes within the responding non-
adherent PBMC population. One obvious co-factor candidate is CD40L which 
was recently shown to play a prominent role in DC dependent activation of 
human NK cells primed with IL-18 (Mailliard 2005). In line with these findings, 
we found that addition of CD40-mediated stimulation (by crosslinked soluble 
CD40L) was needed in order to induce substantial IFN-γ production in co-
cultures of purified autologous αDC1s and purified NK cells (paper I figure 5b). 
These ELISA results were thus in line with FACS data on intracellular 
expression of IFN-.  
Taken together, these data thus suggest that the observed discrepancy as to IFN-
γ production in αDC/NK cell co-cultures using purified NK cells or NK cells 
contained within a total lymphocytes population depends on the absence or 
presence of potentially CD40L-expressing lymphocytes that may upregulate 
CD40L upon stimulation with autologous αDC1s. Since no non-self antigens, 
such as xenogneic proteins from fetal calf serum, were included in the present 
culture media, such cells could possibly be CD1d-restricted NKT cells 
recognizing endogenous glycolipids presented on mature DCs (Mattner 2005) or 
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autoreactive CD4
+
 T cells that become activated during an autologous mixed 
lymphocyte reaction (Scheinecker 1998). 
To summarise, these novel findings presented in Paper I indicate that injected 
human DC1-based clinical grade vaccines have the potential to recruit and 
activate NK cells upon arrival at draining lymph nodes and that this feature may 
be relevant for efficient Th1 polarization by DC based-vaccines. 
PAPER II 
Despite the previous reports of dysfunctional DCs in patients with CLL, 
Kalinski and coworkers showed that functional αDC1s, loaded with γ-irradiated 
autologous tumor cells, could be generated from CLL patients (Lee 2008). 
Compared with PGE2DCs, these αDC1s showed higher expression of several co-
stimulatory molecules without a significant negative impact on tumor antigen 
loading. Furthermore, they also produced higher levels of IL-12p70 and were 
much more effective in inducing functional, tumor-specific CTL responses. 
However, no information was given regarding their ability to produce CXCR3-
ligands or to recruit NK cells and potential CD40 ligand-providing lymphocytes.  
Therefore, the initial aim of paper II was to examine in vitro the capacity of 
tumor-loaded αDC1s and PGE2DCs, derived from CLL patients, to produce a 
chemokine profile that favors the recruitment of NK and potentially CD40L 
expressing NKT cells.   
Tumor-loaded αDC1s show an increased NK and NKT cell recruiting 
capacity compared to PGE2DCs  
In paper II we were able to demonstrate that αDC1s generated from CLL 
patients also produced significantly higher amounts of the CXCR3 ligands 
CXCL9, 10 and 11 than PGE2DCs (paper II figure 1a-c). Importantly, loading of 
αDC1s with necrotic CLL cells had no negative impact on chemokine 
production. Functional studies further demonstrated that αDC1s from CLL 
patients were superior recruiters of NK cells (paper II figure 3). Since NKT cells 
may be potential providers of CD40 ligands when interacting with DCs (Fujii 
2004) and further express a similar chemokine receptor pattern as NK cells 
(Thomas 2003) we also evaluated the NKT-recruiting capacity of vaccine DCs 
and found that supernatants from αDC1s induced a prominent recruitment of 
NKT cells (paper II figure 3). 
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Tumor-loaded αDC1s are superior producers of CCL3/MIP-1α, 
CCL4/MIP-1β and IL-12p70 compared to PGE2DCs, upon CD40 ligation  
Optimal vaccine DCs should most probably mediate a CD4
+
 T cell-dependent 
guiding of rare tumor-specific CD8
+
 T cells to the site of antigen-dependent DC-
CD4
+
 T cell interactions through secretion of CCL3/MIP-1α and CCL4/MIP-1β 
chemokines (Castellino 2006). We therefore evaluated whether differentially 
matured tumor-loaded DCs generated from CLL patients were able to produce 
these chemokines in response to subsequent CD40-ligation, intended to mimic 
the interaction with CD4
+ 
T cell. In order to optimally mimic the in vivo 
situation, previously washed mature DCs were cultured in fresh medium for a 
further 24 hours and subsequently washed before CD40 stimulation by cross-
linked soluble CD40L. This was done to compensate for the time required for 
the DCs to migrate to a draining lymph node. We found that tumor-loaded 
DC1s produced higher amounts of CD8+ T cell-recruiting chemokines 
CCL3/MIP-1α and CCL4/MIP-1β upon CD40 ligation, as compared to 
PGE2DCs (paper II figure 4a-b).  
Of major importance for efficient induction of tumor specific CTLs is also the 
production of Th1-polarizing IL-12p70 (Zitvogel 1996; Xu 2003). In accordance 
with Lee et al (Lee 2008), we could show that tumor-loaded DC1s were 
superior in producing IL-12p70 compared to PGE2DCs after CD40 ligation 
(paper III figure 4c). 
Tumor-loaded PGE2DCs mainly produce Th2 and Treg attracting 
chemokines 
In line with the observations on PGE2DCs from normal blood donors in paper I, 
we found that PGE2DCs generated from CLL patients produced significantly 
higher levels of CCL22/MDC after withdrawal of maturation stimuli, as 
compared to αDC1s (paper II figure 2a).  
This tendency towards Treg recruiting properties associated with PGE2DCs in in 
vitro experiments is further in line with clinical observations on myeloma 
patients, were injected autologous PGE2-matured DCs from myeloma patients 
where shown to expand even more FOXP3
+
 Treg cells than immature DCs and 
they therefore concluded that vaccine-mediated induction of Tregs may be an 
underappreciated effect in clinical trials of human DC vaccination (Banerjee 
2006). Taken together, our in vitro data and these observations by others 
underline the importance of developing optimal DC maturation conditions 
which result in vaccine DCs that avoid interaction with Tregs. 
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To summarise paper II, we found that tumor-loaded αDC1s derived from CLL 
patients produced sustained and substantially higher amounts of CXCR3-ligands 
compared to PGE2DCs. Instead, PGE2DCs produced higher levels of
 
Th2 and 
Treg-attracting
 
chemokines. Functional studies demonstrated that αDC1s from 
CLL patients were superior recruiters of NK cells and also of potential CD40 
ligand-expressing NKT cells and further, upon CD40 ligation, produced higher 
amounts of IL-12p70 and CD8
+
 T cell recruiting CCL3/CCL4 compared to 
PGE2DCs. Importantly, loading of αDC1s with necrotic CLL cells had no 
negative impact on chemokine production. Taken together, these findings 
suggest that functional αDC1s with an imprinted desirable chemokine-producing 
capacity can be generated from CLL patients, supporting the idea that αDC1-
based vaccines have a higher immunotherapeutic potential than PGE2DCs in this 
disease.  
PAPER III 
In an allogeneic DC vaccination setting, priming of the adaptive immune system 
most likely has to be mediated by endogenous APCs that are recruited to the 
injection site in response to inflammatory and chemotactic signals. Tumor 
antigens may be released after NK-cell/CTL-induced apoptosis of the antigen-
loaded allogeneic vaccine cells (Laffont 2006; Laffont 2008), and subsequently 
become ingested, processed and presented by endogenous APCs, including 
monocyte-derived DCs. By trafficking antigens from the site of injection to 
draining lymph nodes, these endogenous DCs may then present antigen to naïve 
and self-MHC-restricted T cells. 
The aim of paper III was therefore to compare the ability of allogeneic 
PGE2DCs and αDC1s derived from healthy blood donors to recruit potential 
endogenous DC precursors such as monocytes and different subsets of 
potentially accessory cells from CLL patients, and further to investigate if the 
recruited monocytes underwent phentotypic and/or functional maturation 
towards desirable Th1-deviating DCs.  
αDC1s provide desirable factors that enable monocyte and accessory 
cell recruitment  
Fundamental for the local recruitment of immune cells is the activation of the 
endothelial cells at the vaccine site that provide signals for adhesion, arrest and 
transmigration of these cells. Two of the most potent inducers of endothelial cell 
adhesion molecules are TNF-α and IL-1β (Langer 2009). In paper III we 
therefore evaluated whether these pro-inflammatory cytokines were produced by 
mature vaccine DCs from time of withdrawal of maturation stimuli, a time point 
when mature vaccine DCs are proposed to be subcutaneously injected. We 
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found that αDC1s produced sustained and higher levels of TNF-α than 
PGE2DCs (paper III figure 1a), while there was a comparable production of IL-
1β (paper III figure 1b).  
Chemokine gradients selectively stimulate the adhered leukocytes to move in 
between endothelial cells and pass into the tissues. Therefore, vaccine DCs 
should produce a desirable chemokine profile in order to facilitate recruitment to 
the injection site of DC-precursors like monocytes and subsets of potential 
accessory cells, including NK, NKT cells and possibly also alloreactive T cells 
(Wallgren 2005), to the injection site. The chemokines CCL2/MCP-1, 
CCL3/MIP-1α and RANTES play an active role in recruiting DC precursors and 
Th1-associated lymphocytes into inflammatory sites. We found that previously 
washed αDC1s produced considerably higher amounts of MCP-1, MIP-1α and 
RANTES, as compared to PGE2DCs (paper III figure 2a-c). In functional 
chemotactic transwell experiments, αDC1s were found to recruit a substantial 
amount of monocytes. However, contrary to the chemokine data, no evident 
difference in monocyte recruitment between αDC1s and PGE2DCs was observed 
(paper III figure 3). In paper I, we also showed that αDC1s from healthy donors, 
in contrast to PGE2DCs, secrete large amounts of CXCR3-ligands after 
withdrawal of maturation stimuli. In accordance with their chemokine profile, 
αDC1s were found to induce a substantially higher recruitment of Th1-
associated lymphocyte subpopulations, compared to PGE2DCs (paper III figure 
4) 
Together, this indicates that injected αDC1s produce factors that would most 
likely support the recruitment of endogenous monocytes and desirable 
lymphocyte subsets to the injection site in vivo.  
Bystander monocytes, matured in an allogeneic αDC1-induced 
environment become phenotypically mature, DC-like cells, within 24 
hours 
When monocytes are recruited from the blood into inflammatory sites they may 
undergo a coordinately regulated process of maturation into DCs. The first step 
in this process is the differentiation of recruited monocytes into immature 
dendritic cells, which may be triggered by transendothelial migration itself 
(Randolph 1998), and by factors such as GM-CSF produced by endothelial cells 
(Kaushansky 1989) and co-recruited NK and NKT cells (Hegde 2007; Zhang 
2007). We therefore investigated the ability of allogeneic mature DCs to induce 
phenotypic maturation in monocytes within the PBMC population from CLL 
patients that had been recruited to a micro-environment created by allogeneic 
vaccine DC and co-recruited lymphocytes. We found that monocytes recruited 
by both αDC1s and PGE2DCs up-regulated the DC-associated phenotypic 
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markers CD40, CD83 and CCR7 within 24 hours of co-culture with mature 
allogeneic vaccine DCs and recruited lymphocytes (paper III figure 5). 
Bystander monocytes primed in an αDC1-induced environment show 
enhanced Th1-deviating capacity 
Further, we examined whether monocytes matured in a αDC1-induced 
environment became functionally mature Th1-deviating DCs. Potential Th1-
deviation was determined by evaluating the typical Th1 cytokine IFN-γ and the 
Th2 cytokines IL-4 and IL-5. Preliminary data indicated that SEB-coated 
monocytes from CLL patients that had been exposed to supernatants from co-
cultures of allogeneic DC1s and recruited PBMCs from CLL patients, may 
activate autologous SEB-reactive T cells into Th1-deviated T cells (paper III 
figure 6a and b). Importantly, SEB-reactive T cells from these primary cultures 
retained their Th1-profile upon subsequent restimulation with SEB-coated 
autologous CLL tumor cells (paper III figure 6c and d). Such prominent and 
sustained Th1-deviating ability was not seen in monocytes that had been 
exposed to supernatants from co-cultures of PGE2DCs and recruited PBMCs 
(paper III figure 6 a-d).  
αDC1s induce IFN-γ production in co-cultures with recruited 
leukocytes from CLL patients 
Although both αDC1s and PGE2DCs induced a phenotypic maturation in 
recruited bystander monocytes, results in paper III indicate that only monocytes 
primed in a αDC1-induced environment seem to favor Th1-deviation. The 
similar capacity of αDC1s and PGE2DCs to induce phenotypic maturation is 
well correlated with our data demonstrating that both αDC1s and PGE2DCs 
passively produce the pro-inflammatory cytokines TNF-α and IL-1β which are 
both known to promote DC maturation (Sallusto 1994; Sallusto 1995). However, 
in order to induce efficient Th1-deviation by DCs, additional instructions by the 
pro-inflammatory cytokine IFN- during DC maturation have been shown to be 
required (Vieira 2000). We therefore looked for possible differences in IFN- 
production in supernatants from co-cultures of allogeneic vaccine DCs and 
recruited PBMCs that were used for bystander monocyte maturation. IFN-γ 
production was only detected in co-cultures of allogeneic DC1s and recruited 
PBMCs (paper III figure 7a and b). These findings highlight the importance of 
recruiting desirable subsets of Th1-associated lymphocytes that contribute to a 
favorable immunogenic microenvironment at the vaccine site, where recruited 
DC-precursors are supposed to be primed.  
To summarise, in paper III we found that tumor-loaded αDC1s derived from 
healthy blood donors recruit monocytes and Th1-associated lymphocytes from 
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CLL patients. Our data indicate that monocytes that become activated in a pro-
inflammatory environment created by allogeneic αDC1s and recruited subsets of 
PBMCs, may undergo phentotypic and functional maturation toward Th1-
deviating DCs. Such Th1-deviating ability was not seen in monocytes that had 
been primed in a PGE2DC-induced environment. However these are still 
preliminary results and further evaluation is needed to confirm these 
observations. 
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CONCLUDING REMARKS  
From the data presented in this thesis, I conclude that the ex vivo conditions 
present during maturation of DC-based cancer vaccines imprint several 
functions, such as stable chemokine profiles, that enable a selective interaction 
between the DCs and different leukocyte subsets, and further that such features 
are of central importance for their potential to induce type-1 polarized immune 
responses.  
SPECIFIC CONCLUSIONS TO GIVEN AIMS: 
 αDC1s but not standard PGE2DCs generated from healthy individuals, 
present a stable and desirable Th1-associated chemokine profile that 
enabled recruitment of NK cells. Only αDC1s were efficient inducers of 
IFN-γ production in autologous NK cells. However, this was dependent 
on the presence of a third cell subset providing concurrent CD40 ligation. 
 Functional autologous tumor-loaded αDC1s with a desirable Th1-
associated cytokine and chemokine profile can also be generated from 
CLL patients. αDC1s were able to recruit NK cells and potential CD40L 
providing NKT cells and following CD40 ligation αDC1s were superior 
producers of factors known to be important for a guided and Th1-deviated 
priming of CD8
+
 T cells.  
 In the allogeneic setting, αDC1s derived from healthy blood donors were 
shown to recruit monocytes and Th1-associated lymphocytes from CLL 
patients. Monocytes primed in such αDC1 but not PGE2DC-induced 
environment seem to undergo maturation toward Th1-deviating DCs.  
Results in this thesis provide some new pieces to the complex puzzle of DC 
biology that may help to design future generations of DC-based vaccines. Our 
findings suggest that to induce efficient Th1-polarized immune responses in 
vivo, DCs must deliver a “selective chemokine-based signal 0” that precedes the 
classical antigen-specific signal 1 and co-stimulatory signal 2, a guiding signal 
that we believe is of central importance for the ability of DCs to deliver the Th1-
polarizing signal 3 and assist tumor-specific T cells to acquire desirable effector 
functions. Our findings further indicate that allogeneic DC1s may be used as 
an adjuvant in anti-cancer vaccination. By using allogeneic vaccine cells loaded 
with antigens derived from allogeneic tumor cells it will be possible to develop a 
fully allogeneic vaccine strategy based on a panel of antigen-loaded vaccine 
cells that can be prepared in advance and cryopreserved before the initiation of 
clinical studies. 
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CLINICAL PERSPECTIVE AND FUTURE DIRECTIONS 
Until now the main focus of research in the field of DC-based immunotherapy 
has been on optimizing the immunostimulatory potential of injected vaccine 
DCs, aimed at boosting the activation and proliferation of tumor-specific CTLs. 
Few clinical studies have considered the presence of the often reported abnormal 
amounts of regulatory T cells or analyzed responses from lymphocyte subsets 
other than CTL e.g., Th1, NK, and NKT cell from a given patient population. 
Furthermore, reported “promising” DC-based vaccinations are often defined by 
success in demonstrating the expansion of circulating tumor-specific CD8
+
 T 
cells which does not necessarily correlate with a clinical anti-tumor response 
(Rosenberg 2005). This emphasizes the need to develop strategies that generate 
effector cells that efficiently target tumors in vivo and further to find out how to 
“prepare” the cancer-induced suppressive environment to enable effector cell-
induced tumor-elimination (Gajewski 2006). 
In order to achieve the goal of long lasting cancer eradication and cure, a 
broader perspective of the cancer field may most probably be required. The 
increasing knowledge of the molecular pathways involved in the pathogenesis of 
cancer and the interaction of the immune system with blood cancer cells as well 
as with different types of solid tumors has provided a rationale for the 
development of novel treatment strategies.  
Perhaps the most unique feature of DC-based cancer vaccines is the fact that the 
vaccine initiates a dynamic process of host immune responses that may be 
exploited in other therapies. There are now several clinical studies that have 
provided evidence of the possibility to boost the effect of different types of cell-
based immunotherapy by a rational combination with other therapies that target 
various mechanisms that are used by tumors to avoid immune-mediated killing. 
Pre-treatment with ionizing radiation (IR) and some chemotherapeutic agents, 
preceding immunotherapy may induce changes in surviving cancer cells, which 
enhance their antigenicity and immunogenicity that promote adaptive immune 
responses (Ganss 2002; Chakraborty 2003; Chakraborty 2004; Garnett 2004; 
Reits 2006; Matsumura 2008; Liu 2010). Dose-dependent effects of the 
cytostatic drug cyclophosphamide, which frequently is used for the treatment of 
leukemias, lymphomas, and solid tumors, have been shown to enhance the 
antitumor efficacy of immunotherapy through the depletion of Tregs (Lutsiak 
2005) and induction of desirable cytokine expression (Bracci 2007). 
Furthermore, combination with antibody therapy or soluble receptors may be 
used to offset inhibitory signals in effector lymphocytes (Peggs 2009) or for the 
blockade of tumor-associated suppressive cytokines (Moore 2001; Li 2006). 
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Further clinical and in vitro studies are needed to explore the potential of such 
immunotherapeutic combination regimens, as well as to provide a better 
understanding of optimal DC maturation conditions, route of vaccination, dose 
and schedule. These will all be keys in the development of the most efficient 
vaccination strategies, with the ultimate goal to improve the cancer patients’ 
survival time with best possible quality of life.  
 
 
Figure 4. DC-based vaccines in combination therapy 
Combination therapy has been shown to improve the clinical efficacy of cell-
based immunotherapy. This may be variously attributed to several factors 
including: a) enhanced presentation of tumor-antigens and other alterations in 
phenotype that facilitate immune-mediated killing b) reduction of Tregs or 
suppressive cytokines and c) boosting of tumor-specific effector cells.
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